Elevation Oncology Stock Forecast, Price & News

Elevation Oncology (NASDAQ:ELEV) Frequently Asked Questions

Is Elevation Oncology a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Elevation Oncology stock.
View analyst ratings for Elevation Oncology or view top-rated stocks.

What stocks does MarketBeat like better than Elevation Oncology?

Wall Street analysts have given Elevation Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Elevation Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Elevation Oncology?

Elevation Oncology saw a increase in short interest in September. As of September 30th, there was short interest totaling 138,700 shares, an increase of 4,234.4% from the September 15th total of 3,200 shares. Based on an average daily volume of 51,100 shares, the days-to-cover ratio is presently 2.7 days. Currently, 1.0% of the shares of the company are sold short.
View Elevation Oncology's Short Interest.

When is Elevation Oncology's next earnings date?

Elevation Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Elevation Oncology.

How were Elevation Oncology's earnings last quarter?

Elevation Oncology, Inc. (NASDAQ:ELEV) announced its quarterly earnings results on Thursday, August, 12th. The company reported ($4.84) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.38) by $4.46.
View Elevation Oncology's earnings history.

What price target have analysts set for ELEV?

4 brokerages have issued 12-month price targets for Elevation Oncology's stock. Their forecasts range from $12.10 to $27.00. On average, they expect Elevation Oncology's share price to reach $20.78 in the next twelve months. This suggests a possible upside of 161.0% from the stock's current price.
View analysts' price targets for Elevation Oncology or view top-rated stocks among Wall Street analysts.

Who are Elevation Oncology's key executives?

Elevation Oncology's management team includes the following people:

• Dr. Shawn Leland Pharm.D., R.Ph., Founder, Pres, CEO & Director (Age 37, Pay $452.74k)
• Mr. Joseph J. Ferra Jr., Chief Financial Officer (Age 45)
• Ms. Tammy Furlong CPA, P.M.P., VP of Fin. & Accounting and Sec.
• Mr. Brian Sullivan, VP of Corp. Devel.

Who are some of Elevation Oncology's key competitors?

Some companies that are related to Elevation Oncology include Graphite Bio (GRPH), Aligos Therapeutics (ALGS), Osiris Therapeutics (OSIR), Talaris Therapeutics (TALS), Finch Therapeutics Group (FNCH), Taysha Gene Therapies (TSHA), Molecular Partners (MOLN), Curis (CRIS), Acumen Pharmaceuticals (ABOS), Tarsus Pharmaceuticals (TARS), Precision BioSciences (DTIL), Gritstone bio (GRTS), Cellectis (CLLS), CEL-SCI (CVM) and Aerie Pharmaceuticals (AERI).
View all of ELEV's competitors.

When did Elevation Oncology IPO?

(ELEV) raised $1 billion in an IPO on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share.

What is Elevation Oncology's stock symbol?

Elevation Oncology trades on the NASDAQ under the ticker symbol "ELEV."

When does the company's lock-up period expire?

Elevation Oncology's lock-up period expires on Wednesday, December 22nd. Elevation Oncology had issued 6,250,000 shares in its public offering on June 25th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Elevation Oncology?

Shares of ELEV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Elevation Oncology's stock price today?

One share of ELEV stock can currently be purchased for approximately $7.96.

How much money does Elevation Oncology make?

Elevation Oncology has a market capitalization of $184.88 million.

How many employees does Elevation Oncology have?

Elevation Oncology employs 8 workers across the globe.

What is Elevation Oncology's official website?

The official website for Elevation Oncology is www.elevationoncology.com.

How can I contact Elevation Oncology?

The company can be reached via phone at 716-371-1125 or via email at [email protected]elevationoncology.com.